The pathogenesis of idiopathic pulmonary fibrosis (IPF) involves a complex interplay of cell
types and signaling pathways. Recurrent alveolar epithelial cell (AEC) injury may occur in …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF) is an irreversible and fatal lung disease that is primarily
found in the elderly population, and several studies have demonstrated that aging is the …

Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium.
Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a …

With the global increase of the elderly population, the improvement of the treatment for
various aging-related diseases and the extension of a healthy lifespan have become some …

Patients with progressive fibrosing interstitial lung diseases (PF-ILDs) carry a poor prognosis
and have limited therapeutic options. A hallmark feature is fibroblast resistance to apoptosis …

Pulmonary fibrosis, a kind of terminal pathological changes in the lung, is caused by
aberrant wound healing, deposition of extracellular matrix (ECM), and eventually …

The use of exogenous mitochondria to replenish damaged mitochondria has been proposed
as a strategy for the treatment of pulmonary fibrosis. However, the success of this strategy is …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with no known
cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure …

Idiopathic pulmonary fibrosis is a chronic disease characterized by progressive lung
scarring that inhibits gas exchange. Evidence suggests fibroblast-matrix interactions are a …